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The pathogenesis of hyperacute transplantation reac-
tions includes the activation of a cascade of nonspecific 
inflammatory reactions that precipitates the destruction 
of the target organ. Platelet-activating factor (P AF) 
represents an important component of these inflamma-
tory cascades. and we have examined the influence of a 
specific PAF receptor antagonist (SRI 63-441) on the 
inhibition of hyperacute rejection in two experimental 
models. the rejection of rat cardiac allografts by presen-
sitized recipients and guinea pig-to-rat and mouse-to-
rat cardiac xenografts. Our results demonstrate that 
inhibition of PAF function by SRI 63-441 has a variable 
effect on the survival of cardiac allografts in presensi-
tized rat recipients. In the ACI to sensitized BN cardiac 
allograft model. the use of SRI 63-441 alone. or in 
combination with CsA. FK506, or prostaglandin Ez 
(PGEz). does not prolong graft survival. As we have 
previously reported, SRI 63-441 does act as a single 
agent to prolong the survival of ACI to sensitized LEW 
grafts, and this survival effect is synergistic when com-
bined with CsA. Here we extend these results to dem-
onstrate that this survival is also extended when FK506 
is used in the ACI-to-LEW model. Concordant mouse-to-
rat cardiac xenografts are also relatively resistant to 
prolongation of graft survival following treatment with 
SRI 63-441 alone or in combination with CsA or FK506. 
Discordant xenografts appear to be more susceptible 
to inhibition of the rejection reaction with SRI 63-441. 
When either donor or recipient animals were treated 
with SRI 63-441 alone, or in combination with CsA or 
FK506, there was significant prolongation of guinea 
pig-to-rat cardiac xenograft survival. These results are 
consistent with our earlier description of the effective-
De&8 of SRI 83-441 iD preventing the rejection of cat-
to-rabbit kidney xenografts. We believe that these re-
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suIts demonstrate that the use of the SRI 63-441 to 
specifically interfere with the function of P AF has the 
effect of prolonging graft survival in those systems in 
which preformed antibody and/or complement activa-
tion are important components of the hyperacute reac-
tion. This synthetic drug is representative of a family of 
compounds whose structure can be modified to balance 
their therapeutic and toxicity activities, and may prove 
to be important components of a poly therapeutic ap-
proach to the control of graft rejection in sensitized 
patients or following discordant xenografting. 
The hyperacute form of organ graft rejection was originally 
recognized in patients who had received kidneys from ABO· 
blood-group incompatible donors (J)- The reaction is mediated 
by the presence of preformed antibody against donor renal graft 
ABO antigens and is associated with endothelial damage sec-
ondary to deposition of antibody and complement (2) and 
vascular thrombosis (3). Hyperacute rejection (HAR)· can also 
be seen in patients who have been stimulated to produce 
antidonor antibodies to specific HLA antigens (4), either be-
cause of the rejection of an HLA incompatible graft, multiple 
blood transfusions, or, secondarily, because of multiple preg-
nancies. 
Experimental studies of the mechanism of HAR have shown 
that the primary target for the reaction is the capillary endo-
thelium of the graft (5, 6). Within 1 min after transplantation, 
widespread blockage of the microvascular system by platelet 
and neutrophil aggregates and fibrin occurs. The reaction de-
pends upon the activation of complement (7), and results in 
vasoconstriction and a disseminated intravascular coagulation 
in the microvasculature_ The occlusion of the microvasculature 
of the graft results in an ischemic necrosis of the transplanted 
organ that shares many of the features of an experimentally 
induced generalized Shwartzman reaction (4). 
Severe injury to vascular endothelium is associated with the 
release of a variety of biologically active mediators of coagula-
tion and inflammation, stimulation of platelet aggregation, and 
modulation of inflammatory cell interaction with the endothe-
• AbbreviatiOlll: HAR, hyperacute rejection; PAF, platelet-activating 
factor; PGEt, prostaglandin Et. 
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lium. Platelet-activating factor (PAF) is one of the more re-
cently recognized biological mediators, and it represents 8 class 
of potent lipid autocoids that have been reported to be impor-
tant in the pathogenesis of acute inflammation (8), endotoxin 
shock (9), and anaphylaxis (10). PAF exhibits a broad spectrum 
of activities, including aggregation and activation of platelets 
and neutrophils, increased vascular permeability, smooth mus-
cle contraction, and the release of vasoactive amines (8, 11). 
More recently, P AF has been implicated as a key biological 
mediator in the pathogenesis of antibody and complement-
mediated hyperacute organ rejection (12). When kidney grafts 
were transplanted to sensitized rabbits, P AF was identified in 
the blood draining the transplanted kidney. PAF was detected 
in the blood effluent within 2-10 min after revascularization 
and was not found in syngeneic controls or unsensitized recip-
ients. Injection of a synthetic, purified P AF into the renal 
artery induced lesions in the kidney that were identical to those 
seen in the Shwartzman reaction. Similar results were obtained 
in vitro when perfusion of isolated rabbit hearts with trans-
plantation alloantibodies was associated with a complement-
dependent release of PAF (13). 
The potential that PAF may play an important role in the 
early initiation of the lesions of HAR has led us to examine the 
influence of specific inhibitors of P AF on hyperacute rejection. 
A variety of specific PAF receptor antagonists have been syn-
thesized and have been reported to block P AF binding to its 
high-affinity receptor. These compounds are capable of inhib-
iting and/or reversing PAF-induced hypotension (14), neutro-
penia (15), bronchospasm (16). endotoxin shock (9), and ana-
phylaxis (10). Our initial studies indicated that a single bolus 
of one of these PAF receptor antagonists (SRI 63-441) at a 
dose of 15 mg/kg was capable of significantly prolonging hy-
peracute rejection by sensitized LEW rats of ACI strain cardiac 
allografts (J 7). This treatment inhibited but did not prevent 
HAR. and, at somewhat higher doses, there was evidence of a 
toxic effect on the recipients. The inclusion of either CsA or 
prostaglandin E2 (PGE2) did not consistently improve the graft 
survival times. The effect of SRI 63-441 was also tested for its 
ability to prevent discordant cat-to-rabbit (17) and pig-to-dog 
(J 8) xenograft reactions, and our results demonstrated signifi-
cant prolongation of graft survival, particularly when the SRI 
63-441 was used in combination with immunosuppressants or 
prostaglandins. 
The current report evaluates in more detail the effect of SRI 
63-441, either alone or in combination with additional phar-
macologic agents. on the rejection of rat cardiac allografts in 
presensitized recipients, and on cardiac survival in a series of 
concordant and discordant xenografts in rats. The SRI 63-441 
compound is a specific PAF receptor antagonist manufactured 
by the Sandoz Company (East Hanover, NJ). It represents one 
of a family of agents that can be synthesized to meet various 
therapeutic requirements. including intravenous or oral admin-
istration. Our results indicate that the use of these compounds 
may be effective in inhibiting humoral effector arms of the 
inflammatory reaction of hyperacute rejection and that the 
effective control of this reaction may be possible when these 
compounds are combined with other therapeutic agents di-
rected at the cellular components of the rejection process. 
MATERIALS AND METHODS 
Araimoll. Commercially available inbred male Lewis (LEW) (RT1 1). 
Brown-Norway (BN) (RT1-). and ACI (RT1") rata weighlnc 200-220 g 
were purchased from Harlan Sprague Dawley (HSD; Indianapolis, IN). 
These strain combinations were selected on the basis ofstrong histoin-
compatibility differences to provide a reproducible and reliable model 
of hyperacute rejection. Hartley guinea pigs (200-220 g, HSD), and 
male inbred B6AF1 mice (25-30 g; Jackson Laboratories, Bar Harbor, 
ME) were used for the discordant and concordant heterotopic heart 
xenografts, respectively. All animals were acclimatized in our animal 
facility for at least 2 weeks prior to investigation and received standard 
rat chow (Wayne Lab-Blox F ·6, Chicago, IL) and water ad libitum. 
Sensitization procedures. Presensitization of LEW and BN recipients 
was achieved by the placement of skin allografts from ACI strain rats. 
The ACI donors were anesthetized with methoxyflurane, and a full-
thickness ventral abdominal skin graft removed. A 2.5-cm circular skin 
graft was transplanted to the dorsum of the LEW or BN recipient and 
fastened with wound clips (Clay·Adams, Parsippany, NJ). The graft 
site was wrapped in plaster bandage (Johnson & Johnson, Chicago. IL) 
for 4 days after the grafting procedure to immobilize the donor graft. 
The grafts were inspected regularly for rejection, and two (ACI ..... BN) 
or three (ACI-LEW) additional grafts were placed on each recipient 
at 2·week intervals. 
Heterotopic cardiac aUograftiTl{!. Heterotopic heart transplants were 
performed 17-20 days following the final skin graft in presensitized 
recipients. Contemporaneous controls receiving vehicle only were per-
formed for each experimental group. The heart grafting was performed 
using a modification of the techniques described by Ono and Lindsey 
(19). The donor animals were anesthetized with sodium pentobarbital 
(40 mg/kg i.p.) and maintained on methoxyflurane via inhalation. The 
vena cavae and pulmonary veins were ligated with 5-0 silk, and the 
pulmonary artery and aorta transected 2-3 mm above their origins in 
the heart. After perfusion of the ventricles and atria with lactated 
Ringer's solution (containing 200 V/ml of heparin), the donor heart 
was placed in a saline bath at 4 ·C. Recipient animals were anesthetized 
with pentobarbital, a midline incision made, and the great abdominal 
vessels dissected free from the left renal vein to the bifurcation. The 
graft was implanted in the abdominal cavity with both anastomoses 
performed in a running end-to-side fashion with 10-0 Novafil on aTE· 
70 needle. Operative times ranged from 30 to 45 min with a success 
rate of approximately 90%. The grafts were evaluated for function by 
abdominal palpation every 30 min for the initial 15 hr and then twice 
daily thereafter. Rejection was considered to have occurred when there 
were no palpable contractions and the condition of the donor heart was 
confirmed by laparotomy and by histologic evaluation. All experimental 
animals were weighed daily. 
Pharmacologic Agents 
PAF antagonist (SRI 63-441). The PAF inhibitor SRI 63-441 
was kindly supplied by Sandoz Research Institute (East Han-
over, NJ). This synthetic compound represents one of the most 
potent receptor antagonists of PAF responses and is a substi-
tuted (tetrahydrofuranyl- [methoxyphosphinyloxy )ethyl) quin-
olinium compound (MW 662) (I5). The powdered form was 
reconstituted in 0.68% sodium acetate buffer and 0.9% sodium 
chloride (pH 5.3) to a final concentration of 10 mgfml and was 
placed in a warm water bath (26-28°C) for 5 min. A single 
bolus injection was administered via the inferior vena cava to 
the recipient 4 min prior to revascularization of the donor 
heart. In selected experiments. a single injection of the drug 
(30 mg/kg) was administered to the donor 4 min prior to harvest 
of the heart graft. The dosage levels evaluated in the recipients 
for the different experiments are listed in the individual tables. 
FK506. A crystalline powdered form of FK506 (MW 882) 
was supplied by Fujisawa Pharmaceutical Company, Ltd. 
(Osaka. Japan). A final concentration of 1.28 mgfml was pre-
pared in 0.9% sodium chloride. FK506 was administered at a 
dosage of 1.28 mg/kg/day for a duration of 14 days (or until 
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rejection) by intramuscular injection. Administration of the 
drug began 3 days prior to transplantation (day -3). In selected 
experiments, oral FK506 was administered by gavage at a 
dosage of 3.2 mg/kg/day using the drug preparation and sched· 
ule as described above. 
Cyclosporine. A commercially available formulation of CsA 
(100 mg/kg) from Sandoz Pharmaceutical Corporation (East 
Hanover, NJ) was diluted in olive oil to a final concentration 
of 10 mg/ml and administered orally at a dosage of 15 mg/kg/ 
day beginning 3 days prior to transplantation (day -3) and 
continued for a maximum of 14 days (or until graft rejection). 
Statistics. Graft survival curves were estimated using the 
Kaplan.Meierproduct·limit method. Differences in the median 
survival times of the various treatment groups were compared 
using the generalized Wilcoxon test statistics. The P·values for 
pairwise comparisons are given in the tables, and if statistically 
significant differences (P<0.05) exist after adjustment of alpha 
levels for multiple comparisons the values are indicated in the 
table footnotes. 
Prostaglandin E2 (PGEJ. Prostaglandin E2 was supplied by 
the Upjohn Company of Kalamazoo, Michigan. The PGE2 was 
reconstituted in a stock solution of 1 mg in 100 ~I of ethanol. 
This solution was then diluted in 0.9% sodium chloride and 
administered 30 min prior to rev8SCularization at a dosage of 3 
mg/kg/day by continuous intravenous infusion. 
Histology. Tissue specimens for histologic studies were col· 
lected after rejection of the cardiac grafts. At the time of 
rejection, biventricular segments of the heart and sections of 
kidney were fixed in 10% buffered formalin solution and em· 
bedded into paraffin after fixation. Sections were cut at 3 ~ and 
stained with hematoxylin and eosin. 
RESULTS 
Hypersensitized Recipients 
SRI 63·441 alone in BN recipients. Cardiac allograft survival for 
hypersensitized control and treated animals is summarized in Table 1. 
Our previous experiments using presensitized LEW rats and ACI 
donors had demonstrated that significant prolongation of graft survival 
could be induced by treatment with SRI 63·441 alone, and this set of 
experiments was attempted to repeat those observations with different 
strain combinations. As seen in Table I, the sensitized BN animals 
consistently rejected their ACI grafts in a hyperacute fashion (MST 
68.0±lS.1 min; n=39). Treatment of sensitized rats with SRI 63-441 
as a single intravenous bolus prior to revascularization did not result 
in a prolongation of the graft survival. One group (20 rng/kg) actually 
had shorter survival times than the control group (MST=27.0 min, 
P=0.07). 
TABLE 1. Effect of SRI 63·441 alone or in combination with CsA, FK506, or prostaglandin (PGE.) on ACI C'ardiac allograft survival in 
presensitized BN rats 
Treatment n Graft survival time (min) Median :!:SE' P value 
Control 39 3, 4, 4, 6, 9, 12, 15, 16, 16, 68.0±15.1 
17,20,25,31,34,35,46, 
52,52,67,68,70,75,82, 
90, 104, 110, 115, 133, 
144, 165, 192, 195, 283, 
285,314,350,484,600, 
1080 
SRI 63·«1, 15 mg/kg 9 41,57,67,80,95,107,109, 95.0±22.4 0.37 
210, 256 
SRI 63·441, 20 mg/kg 7 6,16,18,27,41,49,60 27.0±I1.S 0.07 
SRI 63·441, 30 mglkg (donor pretreat· 6 28, 132, 143, 160, lS2, 2S0 143.0±17.2 0.21 
ment) 
CaA alone 7 6,23,420,540,1440,1440, 540.0±lS7.1 O.OS 
2880 
CsA+SRI63·441, 10 mglkg 5 99,159,262,273,307 262.0±112.8 O.OS 
C.A+SRI63-441, 15 mglkg 5 65,67,87,145,291 87.0±21.9 0.40 
FK506 alone 7 120,169,212,230,240, 230.9±23.6 0.02 
247,468 
FK506+SRI63·441, 15 mglkg 8 105, 107, 121, 128,240, 128.0±B4.2 0.02 
319, 569, 7200 
PGE,only 7 11,27, SO, 75, 149, 154, 7S.0±32.7 O.Sl 
210 
PGE,+SRI 63-441,10 mg/kg 6 35,48,60,166,368,420 6O.0±72.3 0.30 
PGE,+SRI63·441, 15 mg/kg 8 15,30,36, 57, 60,61, 77, 57.0±17.0 0.62 
155 
• Asymptotic standard error. 
------ - --~---
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SRI 63·441 and immunosuppression with CsA or FK506. Animals 
treated with either CsA or FK506 alone or in combination with SRI 
63·441, also failed to demonstrate prolongation of ACI cardiac graftS 
transplanted into sensitized BN rats (Table 1). Neither immunosup· 
pressive agent administered alone had the ability to prevent hyperacute 
rejection, and the combination of either drug with SRI 63·441 does not 
improve the effectiveness of the treatment. Although there was pro· 
longed survival of the grafts in several groups, the P·values were not 
significant at the adjusted alpha levels of P=O.01. 
results were not statistically significant in either combination. The 
ACI·to·LEW donor· recipient combination demonstrated a greater sen· 
sitivity to the effect of SRI 63·441, and we tested the effectiveness of 
FK506 in this combination to establish whether a similar sensitivity 
could be seen with this drug (Table 3). In this combination a significant 
prolongation of allograft survival was evident when FK506 was given 
alone or in combination with SRI 63·441 at dosages of either 10 or 15 
mg/kg. 
The results we obtained with the treatment of the sensitized BN 
recipients with CsA were similar to those we observed earlier for the 
ACI·to-LEW combination (Table 2 and [17)). Although there may be 
some prolongation of graft survival following treatment with CsA, the 
SRI 63·441 and prostaglandin E2• In order to determine if the effect 
of SRI 63·441 could be enhanced by using it in combination with other 
agents that inhibit the inflammatory components of rejection, we 
included PGE. in the treatment regimen. PG~ is one of a group of 
short·lived,local·acting messengers that generally act to protect against 
TABLE 2. Effect of SRI 63·441 alone or in combination with FK506 on ACI cardiac allograft survival in presensitized LEW rats 
Treatment n 
Control 74 
SRI 63·441, 10 mg/kgb 10 
SRI 63·441, 15 mg/kgb 20 
FK506 11 
G raft survival time (days) 
0.001,0.002,0.002,0.003,0.003, 
0.003, 0.003, 0.004, 0.005, 
0.006,0.006,0.007, om, 0.01, 
0.01, om, 0.01, 0.01, 0.01, 
0.02, 0.02, 0.02, 0.02, 0.02, 
0.02, 0.02, 0.02, 0.02, 0.03, 
0.03, 0.03, 0.03, 0.03, 0.03, 
0.04, 0.04, 0.04, 0.04, 0.04, 
0.04, 0.05, 0.05, 0.05, 0.05, 
0.06, 0.06, 0.06, 0.06, 0.07, 
0.08,0.08,0.10,0.13,0.13, 
0.15, 0.24, 0.24, 0.26, 0.26, 
0.27,0.27,0.29,0.31,0.33, 
0.42, 0.42, 0.42, 0.42, 0.60, 
0.67,0.83,0.88, 1.0, 1.0 
0.003, 0.02, 0.04, 0.05, 0.06, 
0.14, 1.13, 1.19, 2.19, 4.0 
0.03, 0.08, 0.09, 0.12, 0.13, 0.15, 
0.17,0.32,0.42,0.5,1.17,2, 
2.7,3,3,3.5,4,4,4,5 
0.01,0.03,0.05, 0.06, 0.1, 0.27, 
1.4, 2, 3, 11,50 
0.85, 4, 4, 8, 13, 20, 29, 39 
0.06,0.07,0.07,0.10,5,8,9, IS, 
____________________________________ 1~9~,27,31,50 
FK506+SRI 63·441, 10 mg/kg 8 
FK506+SRI 63·441, 15 mg/kg 12 
• Asymptotic standard error. 
b Modified data from reference 17. 
, Significant at the adjusted alpha level (0.02). 
Median :tSE" P value 
0.04±0.01 
0.06±0.07 0.08 
01.2±1.1 <0.0001' 
0.2±0.7 0.01' 
8.0±6.4 0.0001 ' 
8.0±3.5 0.0001' 
TABLE 3. Effect of SRI 63·441 alone or in combination with CsA, FK506, or prostaglandin (PGE,) on guinea pig·to·rat cardiac xenograft 
aurvival 
Treatment n Graft survival time (min) Median ±SE" Pvalue 
Control 8 5, 5, 5, 5, 6, 7, 8, 9 5.0b 
SRI 63·441, 10 mg/kg 6 10,12,27,31,54,62 27.0±11.6 0.0009' 
SRI 63·441, 15 mg/kg 7 11, IS, 19,64,90, 117, 127 64.0±58.8 0.0001' 
SRI 63·441, 20 mg/kg 5 II, 21, 44, 68, 99 44.0±25.2 0.002' 
SRI 63·441, 30 mg/kg (donor pretreat· 6 7,10,26,26,27,31 26.0±9.2 0.004' 
ment) 
CIA 6 6,7,7,8, 11, 15 7.0±0.8 0.07 
FK506 8 5,6,8,13,16,41,53,67 13.0±5.7 0.02 
PGE, 6 6,6, 10, 11, 12, 19 10.0±3.1 0.02' 
CIA+SRI 63·441, 15 mg/kg 6 13,15,19,55,68,75 19.0±24.5 0.0009" 
FK506+SRI 63·441,15 mg/kg 8 10, 11, 11, 15, 15, 17, 19, 15.0±2.7 0.0001~ 
45 
PGE,+SRI 63·441, 15 mg/kg 6 8,17,17,19,26,60 17.0±4.5 0.002' 
• Asymptotic atandard error. 
• Asymptotic atandard error cannot be calculated 
, Significant at the adjusted alpha level of 0.02. 
4 Significant at the adjusted alpha level of 0.01. 
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and/or limit acute cellular injury. Our previous work with renal trans-
plantation in the pig-to-dog xenograft model (I8) suggested that SRI 
63-441 and PG~ may act synergistically to prolong discordant xeno-
graft reactions. Treatment of sensitized BN recipients of ACI heart 
grafts with prostaglandin (PGE,), either alone or in combination with 
SRI 63-441, did not, however, result in significantly prolonged cardiac 
allograft survival (Table 1). In no case did graft survival exceed 7 hr. 
Xenotransplantation 
Both discordant (widely disparate species combinations) and 
concordant (phylogenetically similar species combinations) an-
imal groups were studied in order to determine whether either 
of these two xenograft reactions could be influenced by inhibi-
tion of PAF function by SRI 63-44l. 
Guinea pig-to-rat cardiac xenografts-SRI 63-441 alone. The 
median survival time to asystole of the cardiac xenografts 
transplanted from guinea pig donors to rat (LEW) recipients 
was 5.0 min (Table 3). Significant prolongation (up to 10-fold) 
was achieved either when the donor was pretreated with 30 
mgjkg SRI 63-441 prior to harvest or when recipients received 
10, 15, or 20 mglkg of this agent prior to revascularization. 
Guinea pig-to-rat cardiac xenografts-SRI 63-441 and addi-
tional pharmacologic agents. Multiple administrations of either 
CsA or FK506 were not associated with significant prolongation 
of guinea pig-to-rat cardiac grafts (Table 3). However, when 
SRI 63-441 was combined with either FK506 or esA, a 3-6-
fold increase, respectively, in graft survival was observed. 
As we have described earlier for discordant pig-to-dog xeno-
graft reactions (18), PG~ was also effective, particularly when 
Il8ed in combination with SRI 63-441, in modulating HAR 
8880Ciated with the discordant guinea pig-to-rat xenografts 
(Table 3)_ 
Hi3topathology: When the tissue sections from these grafts 
were reviewed, the classic histopathologic features of discordant 
cardiac xenograft rejection were observed. The control grafts 
exhibited widespread obstruction of small vessels with platelet-
fibrin thrombi and, because of the rapid rejection times, few 
other pathologic changes. In those animals that survived for 
longer periods of time, there was mild-to-severe intramyocar-
dial hemorrhage and evidence of endothelial damage to small 
vessels. The endothelial damage consisted of ballooning degen-
eration of the endothelium, particularly in small arteries. There 
was no evidence of qualitative differences in the histopathologic 
changes seen between animals within individual treatment 
groups, suggesting that the appearance of the endothelial dam-
age and hemorrhage was due to the development lesions with 
the passage of time. These results are consistent with our 
previous descriptions of the pathologic features of the hypera-
cute rejection of cardiac allografts in presensitized LEW recip-
ients of ACI hearts treated with SRI 63-441 and/or CsA (17). 
Mouse-to-rat xenografts-SRI 63-441 alone or in combination 
with pharmacologic agents. In the concordant species combi-
nation of mouse-rat, the control rejection time was consist-
ently 3 days. The administration of SRI 63-441 at 15 mg/kg 
failed to extend organ survival (Table 4). Similarly, multiple 
administration of therapeutic dosages of either FK506 or CsA 
had no effect when given alone. When FK506 was combined 
with SRI 63-441, 3 out of 5 grafts survived 4 days. This 
prolongation, however, was not statistically significant (alpha 
level 0.008). Furthermore, a beneficial response was not evident 
following the intravenous infusion of 3 mg/kg/day of PGE2, 
either alone or in combination with the PAF antagonist. 
DISCUSSION 
Our experimental results demonstrate that a potent synthetic 
antagonist (SRI 63-441) to platelet-activating factor is capable 
of interfering with the hyperacute rejection of foreign allografts 
and discordant xenografts. We have examined the effectiveness 
of SRI 63-441 in preventing hyperacute rejection of heterotopic 
cardiac grafts in two experimental models, heart allografts 
exchanged between donor and recipient rat strains in which 
the recipient had been preimmuni:aed with donor skin grafts 
and rat recipients of discordant (guinea pig) and concordant 
(mouse) xenografts. The hyperacute rejection of heart allografts 
by a recipient preimmunized with donor tissues depends upon 
the presence of circulating antidonor antibodies that bind to 
the graft immediately following transplantation and precipitate 
a rejection within a few minutes. The rapid rejection of discor-
dant xenografts is thought to represent a similar antibody-
mediated rejection mechanism that depends upon the existence 
of natural recipient antidonor species antibodies (20), although 
the formal demonstration of host antidonor antibody is lacking 
in selected systems (21). 
The PAF antagonist SRI 63-441 is capable of prolonging 
cardiac allograft survival in some, but not all, rat cardiac 
allograft combinations. We have previously demonstrated that 
sensitized LEW recipients of ACI heart grafts display a re-
markable prolongation (lOx) of graft survival when the recip-
ients are treated with SRI 63-441 immediately prior to trans-
plantation (17). In the present study, our results demonstrate 
that FK506 alone is capable of prolonging graft survival in the 
sensitized rat model and that the inclusion of SRI 63-441 results 
in additional improvement in graft survival for this type of 
hyperacute rejection, perhaps as a result of the simultaneous 
interference with humoral and cellular inflammatory processes. 
TABLE 4. Effect of SRI 63-«1 alone or in combination with CsA, FK506, or prostaglandin (PGE.) on mouse-to-rat cardiac xenograft survival 
Treatment Graft survival time Median survival· Pvalue n (days) 
Control 8 3, 3, 3, 3, 3, 3, 3, 3 3.0 
SRI 63-441,15 m,/kg 8 3, 3, 3, 3, 3, 3, 3, 4 3.0 0.32 
CIA alone 8 3, 3, 3, 3, 3, 3, 3, 3 3.0 
FK506 7 3, 3, 3, 3, 3, 3, 3 3.0 
PGE, 5 3,3,3,4,4 3.0 0.06 
CaA+SRI 63-441, 15 m&/ka 6 3, 3, 3, 3, 3, 4 3.0 0.25 
FKlS06+SRI 63-441, 15 mg/kg 5 3,3,3,3,3 3.0 
FKlS06 oraI+SRI 63-«1, 15mg/kg 5 3,3,4,4,4 4.0 0.02 
PGE,+SRI 63-«1, 15 milk' 5 3,3,3,3,4 3.0 0.21 
• Alymptotic standard error cannot be calculated. 
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Despite the effectiveness of SRI 63-441 in preventing HAR 
in the ACI/LEW combination, however, the exchange of car-
diac allografts between ACI donors and sensitized BN recipi-
ents was not associated with significantly prolonged survival 
following SRI 63-441 treatment. This was true for pretreatment 
of the recipient or donor with SRI 63-441 alone or in combi-
nation with CsA, FK506, or PGE2• These results may reflect 
immunogenetic differences between the LEW and BN strains 
as recipients (22), or that the intensity of the antidonor anti-
body response has an important effect on modulating the 
effectiveness of the treatment. 
While the ability of SRI 63-441 to modulate HAR in the 
presensitized allograft model may be variable, the ability of this 
compound to interfere with discordant xenograft combinations 
appears to be more consistent. We have previously demon-
strated that pig-to-dog renal xenografts can be prolonged if the 
recipient is treated with the combination of SRI 63-441 and 
either one of two prostanoids, PGI2 or PGE1 (18). Cat-to-rabbit 
discordant xenografts can be prolonged by recipient pretreat-
ment of SRI 63-441 alone and do not depend upon the addi-
tional action of prostanoids (17). The effectiveness of the 
prostanoids in enhancing the effect of the PAF antagonist may 
be the result of their ability to inhibit the acute inflammatory 
reaction, perhaps via platelet function or their influence on the 
clotting cascade (23). The current studies demonstrate that 
SRI 63-441 alone was clearly able to prolong grafts exchanged 
between the discordant guinea pig-to-rat combination. The 
addition of CsA or FK506 to the SRI 63-441 treatment was 
also associated with prolongation of graft survival, although 
neither of these immunosuppressive agents appeared to en-
hance the activity of the P AF antagonist. Recipient treatment 
with PG~ alone was associated with significantly prolonged 
graft survival for the guinea pig-to-rat xenografts, and the 
addition of SRI 63-441 resulted in improved graft survival times 
that were comparable to those seen with SRI 63-441 alone and 
in various combinations with CsA and FK506. 
Since the original description of antibody-mediated hypera-
cute rejection of the kidney, numerous experimenta1and clini-
cal studies have attempted to define the precise mechanism(s) 
of this destructive process (24-27). While controversy remains 
over which antibodies and under what circumstances immedi-
ate graft dysfunction is caused, HAR must be regarded as the 
product of a complex immune/inflammatory reaction. The 
initial antibody-mediated injury (IgG and IgM) to the vascular 
endothelium (5) is followed by secondary vasoconstriction (28), 
the recruitment of polymorphonuclear leukocytes (25), and 
aggregated platelets (29, 30), with intravascular coagulation 
(29, 31). The combination of vasoconstriction and the platelet-
leukocyte-plugs occlude the small arterioles and capillaries 
producing ischemic necrosis of the graft. The recruitment of 
leukocytes and platelets may initially be due to immune adher-
ence and specific aggregation, and then later due to stasis and 
nonspecific entrapment. This entire process is accompanied by 
fibrin deposition and rapid occlusion of the vascular system of 
the organ (4,32). Platelet-activating factor has been proposed 
u • key biological candidate in the overall evolution of this 
type of inflammatory process and a central mediator in the 
pathogenesis of antibody-mediated hyperacute rejection (12, 
13). Hyperacute renal allograft rejection in sensitized rabbits 
is aseociated with a local intravascular release of P AF and 
morphologic and histologic characteristics of HAR in all the 
recipients (12). 
Despite the complexity of the inflammatory and clotting 
systems involved in the hyperacute rejection of vascularized 
organs, our results demonstrate that interference with the 
function of PAF has the effect of prolonging graft survival in 
those systems in which preformed antibody and/or complement 
activation are important components of the reaction. The effect 
of SRI 63-441 alone is not sufficient to provide for a practical 
method to prevent hyperacute rejection, but these experiments 
do confmn the central role of PAF in the inflammatory cascade 
that destroys heart and kidney grafts undergoing HAR in both 
the highly sensitized recipient and following discordant xeno-
transplantation. Of particular interest is our observation that 
donor pretreatment may also influence the outcome of both the 
allogeneic and xenogeneic hyperacute reactions. These results 
suggest that SRI 63-441 may be acting to prevent the release 
of important donor mediators, stabilize the membranes of donor 
cells, such as endothelium, or perhaps alter the antigenicity of 
the endothelial cell surfaces. It is very likely that a combination 
of approaches, affecting both the immunologic and nonimmu-
nologic components of this complex phenomenon, will be nec-
essary to achieve significant control of HAR and that antago-
nists to the action of platelet-activating factors may play a 
central role in this form of therapy. 
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